Market Overview:
The global candesartan cilexetil API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hypertension and rising demand for candesartan cilexetil tablets and capsules. In terms of type, the purity greater than or equal to 98% segment is expected to account for a larger share of the global market in 2018. By application, the tablets segment is expected to account for a larger share of the global market in 2018. Geographically, North America is estimated to dominate the global candesartan cilexetil API market in 2018.
Product Definition:
Candesartan cilexetil is an angiotensin II receptor antagonist. It is used to treat high blood pressure (hypertension) and congestive heart failure.
PurityGreater than or equal to98%:
The global Candesartan Cilexetil API market is expected to grow at a lucrative rate during the forecast period. The growth of this market can be attributed to factors such as growing demand for cost-effective drugs, increasing prevalence of hypertension and diabetes, rise in geriatric population prone to diseases such as renal failure and congestive heart failure along with other cardiovascular disorders.
PurityGreater than or equal to99%:
Purity Greater than or equal to 99% is a type of Pharmaceutical Ingredient that has been used in the preparation of various medicines for more than 100 years. It is also known as Pure Substance, Highly Purified substance or Highly Refined Powder.
It can be extracted from plant and animal matter by means of distillation and crystallization techniques.
Application Insights:
Based on the application, the global candesartan cilexetil API market is segmented into candesartan cilexetil tablets and candesartan cilexetil capsule. The tablet was estimated as the largest revenue-generating segment in 2017 due to extensive usage for treating hypertension. Moreover, increasing R&D activities pertaining to new indications and additional benefits over other angiotensin-converting enzyme inhibitors are expected to drive growth during the forecast period.
The capsule formulation of Candex is used for prevention of heart diseases such as stroke & heart attack among adults aged more than 60 years suffering from high blood pressure levels along with diabetes mellitus type 2. This factor is anticipated to boost product demand in this region over the next few years.
Regional Analysis:
North America dominated the global candesartan cilexetil API market in 2017. This is attributed to the presence of a large patient pool and high healthcare expenditure in this region. In addition, increasing awareness about hypertension treatment options and favorable government initiatives are some other factors contributing to the growth of this regional market. Asia Pacific is expected to witness lucrative growth over the forecast period owing to improving economic conditions, growing disposable income levels, rising population awareness about health issues and availability of advanced treatment methods for various diseases including hypertension.
The key players operating in each regional markets are Takeda Canada Inc.
Growth Factors:
- Increasing prevalence of hypertension and other cardiovascular diseases: The global prevalence of hypertension is estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025. This will create a large pool of patients who will require treatment, thereby driving the demand for candesartan cilexetil API.
- Growing awareness about the benefits of early diagnosis and treatment: There is an increasing awareness among people about the importance of early diagnosis and treatment for various diseases, including hypertension. This is likely to drive the demand for candesartan cilexetil API in the coming years.
- Rising incidence of lifestyle-related disorders: The incidence of lifestyle-related disorders such as obesity and diabetes is on the rise globally, which has led to an increase in cases of hypertension as well. This will create a large market for candesartan cilexetil API in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Candesartan Cilexetil API Market Research Report
By Type
PurityGreater than or equal to98%, PurityGreater than or equal to99%
By Application
Candesartan Cilexetil Tablets, Candesartan Cilexetil Capsule
By Companies
Tapi Teva, Jiangxi Synergy Pharma, Ningbo Menovo Pharma, Tianyu Pharma, Shaoxing Hantai Pharmaceutical, Zhejiang Huahai Pharmaceutical, Chempro Group, Suanfarma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Candesartan Cilexetil API Market Report Segments:
The global Candesartan Cilexetil API market is segmented on the basis of:
Types
PurityGreater than or equal to98%, PurityGreater than or equal to99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Candesartan Cilexetil Tablets, Candesartan Cilexetil Capsule
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tapi Teva
- Jiangxi Synergy Pharma
- Ningbo Menovo Pharma
- Tianyu Pharma
- Shaoxing Hantai Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- Chempro Group
- Suanfarma
Highlights of The Candesartan Cilexetil API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PurityGreater than or equal to98%
- PurityGreater than or equal to99%
- By Application:
- Candesartan Cilexetil Tablets
- Candesartan Cilexetil Capsule
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Candesartan Cilexetil API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Candesartan cilexetil is an oral medication used to treat hypertension. It works by reducing the amount of blood that flows through your veins.
Some of the major players in the candesartan cilexetil api market are Tapi Teva, Jiangxi Synergy Pharma, Ningbo Menovo Pharma, Tianyu Pharma, Shaoxing Hantai Pharmaceutical, Zhejiang Huahai Pharmaceutical, Chempro Group, Suanfarma.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Candesartan Cilexetil API Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Candesartan Cilexetil API Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Candesartan Cilexetil API Market - Supply Chain
4.5. Global Candesartan Cilexetil API Market Forecast
4.5.1. Candesartan Cilexetil API Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Candesartan Cilexetil API Market Size (000 Units) and Y-o-Y Growth
4.5.3. Candesartan Cilexetil API Market Absolute $ Opportunity
5. Global Candesartan Cilexetil API Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Candesartan Cilexetil API Market Size and Volume Forecast by Type
5.3.1. PurityGreater than or equal to98%
5.3.2. PurityGreater than or equal to99%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Candesartan Cilexetil API Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Candesartan Cilexetil API Market Size and Volume Forecast by Application
6.3.1. Candesartan Cilexetil Tablets
6.3.2. Candesartan Cilexetil Capsule
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Candesartan Cilexetil API Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Candesartan Cilexetil API Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Candesartan Cilexetil API Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Candesartan Cilexetil API Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Candesartan Cilexetil API Demand Share Forecast, 2019-2026
9. North America Candesartan Cilexetil API Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Candesartan Cilexetil API Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Candesartan Cilexetil API Market Size and Volume Forecast by Application
9.4.1. Candesartan Cilexetil Tablets
9.4.2. Candesartan Cilexetil Capsule
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Candesartan Cilexetil API Market Size and Volume Forecast by Type
9.7.1. PurityGreater than or equal to98%
9.7.2. PurityGreater than or equal to99%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Candesartan Cilexetil API Demand Share Forecast, 2019-2026
10. Latin America Candesartan Cilexetil API Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Candesartan Cilexetil API Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Candesartan Cilexetil API Market Size and Volume Forecast by Application
10.4.1. Candesartan Cilexetil Tablets
10.4.2. Candesartan Cilexetil Capsule
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Candesartan Cilexetil API Market Size and Volume Forecast by Type
10.7.1. PurityGreater than or equal to98%
10.7.2. PurityGreater than or equal to99%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Candesartan Cilexetil API Demand Share Forecast, 2019-2026
11. Europe Candesartan Cilexetil API Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Candesartan Cilexetil API Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Candesartan Cilexetil API Market Size and Volume Forecast by Application
11.4.1. Candesartan Cilexetil Tablets
11.4.2. Candesartan Cilexetil Capsule
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Candesartan Cilexetil API Market Size and Volume Forecast by Type
11.7.1. PurityGreater than or equal to98%
11.7.2. PurityGreater than or equal to99%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Candesartan Cilexetil API Demand Share, 2019-2026
12. Asia Pacific Candesartan Cilexetil API Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Candesartan Cilexetil API Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Candesartan Cilexetil API Market Size and Volume Forecast by Application
12.4.1. Candesartan Cilexetil Tablets
12.4.2. Candesartan Cilexetil Capsule
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Candesartan Cilexetil API Market Size and Volume Forecast by Type
12.7.1. PurityGreater than or equal to98%
12.7.2. PurityGreater than or equal to99%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Candesartan Cilexetil API Demand Share, 2019-2026
13. Middle East & Africa Candesartan Cilexetil API Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Candesartan Cilexetil API Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Candesartan Cilexetil API Market Size and Volume Forecast by Application
13.4.1. Candesartan Cilexetil Tablets
13.4.2. Candesartan Cilexetil Capsule
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Candesartan Cilexetil API Market Size and Volume Forecast by Type
13.7.1. PurityGreater than or equal to98%
13.7.2. PurityGreater than or equal to99%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Candesartan Cilexetil API Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Candesartan Cilexetil API Market: Market Share Analysis
14.2. Candesartan Cilexetil API Distributors and Customers
14.3. Candesartan Cilexetil API Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Tapi Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Jiangxi Synergy Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Ningbo Menovo Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Tianyu Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Shaoxing Hantai Pharmaceutical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Zhejiang Huahai Pharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Chempro Group
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Suanfarma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
